Quantcast Biolucent Acquired By Hologic For $70 Million
Search by tag or site Login to my blog ? Start my own blog














TheMoneyBlogs
Home
About
Create your own blog
Contact us
Vote for this blog!

BioHealth Investor

BioHealth Investor (BHI) is a blog and journal focused on providing updated commentary and financial news from the biotech and medical technology industry. BHI's content is featured on Yahoo!Finance, Google Finance, TheStreet.com, SeekingAlpha.com and many other blogs and websites. BHI is also a proud member of The Business of Biotech Network, and the Investors Blog Network.

Biolucent Acquired By Hologic For $70 Million

Posted on 06/23/2007 09:37:38 | Link | Post Comment
by Sara Calabro
Med Tech Sentinel



BioLucent, a Aliso Viejo, CA-based company that makes breast cushions for increased comfort during mammographies, has been scooped up by Hologic (HOLX), a diagnostic imaging company focused on women’s health, for $70 million.

Of utmost importance to the acquisition for Hologic is BioLucent’s MammoPad breast cushion, a radiolucent foam cushion that covers the cold, hard surfaces of mammography equipment. The patented device is designed to reduce the discomfort that inhibits many women from getting regular mammograms. According to the companies, MammoPad is the standard of care in about 20% of mammography facilities in the U.S., and it has been used by more than 10 million women.

The total value of the transaction could reach $85 million, as the agreement includes a two-year earn out on top of the purchase price. The earn-out will be payable in two annual cash installments totaling up to $15 million based on BioLucent achieving certain revenue targets. The $70 million purchase price will consist of $5 million in cash and $65 million in whatever form Hologic chooses — cash, common stock or a combination of the two.

BioLucent also does work in the area of brachytherapy. At the closing of the Hologic transaction, that business will be spun off into a newly created, independent company called Cianna Medical. It will manufacture BioLucent’s SAVI breast-brachytherapy device.

BioLucent’s 2006 revenues were approximately $17 million, a 42% jump from 2005.



RELATED READING:
- Amgen Announces Another Acquisition
- NxStage Hopes $79 Million Acquisition Brings Profitability
- Bespak to Acquire Emergent for $38M



Med Tech Sentinel is a regular contributor to BioHealth Investor
________________
Stock Quote or
Examples
Morpheus Trading - Mon Jul 21, 2008 08:33AM
NOTE: Please click on the charts below to enlarge them if [read more]
Morpheus Trading - Mon Jul 21, 2008 08:31AM
NOTE: Please click on the charts below to enlarge them i [read more]
Millionaire Now! by Larry Nusbaum - Tue Jul 22, 2008 09:23AM
Hedge funds have made billions this year shorting the banks, [read more]

PREMIER SPONSORED LINKS

Most Visited Blogs | Most Popular Blogs | Most Recent Blogs | Contact Us | Terms and conditions | Privacy Policy

The columns, articles, message board posts and any other features provided on TheMoneyBlogs.com are provided for personal finance, education and investment information and are not to be construed as investment advice. Under no circumstances does the information in this content represent a recommendation to buy, sell or hold any security. The views and opinions expressed in an article or column are the author's own and not necessarily those of TheMoneyBlogs.com and there is no implied endorsement by TheMoneyBlogs.com of any advice or trading strategy. The analysts and employees or affiliates of TheMoneyBlogs.com may hold positions in the stocks or industries discussed here. Your use of this and all information contained on TheMoneyBlogs.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.

Copyright © 2008 The Connors Group, Inc.